The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 1.00 (5.714%)
Open: 18.00
High: 18.00
Low: 18.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of LeanBiome in Muscletech

15 Jan 2024 07:00

RNS Number : 5934Z
OptiBiotix Health PLC
15 January 2024
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of LeanBiome® in Muscletech®

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare announces the forthcoming launch of LeanBiome® in Muscletech®, one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company (see About Us · MuscleTech). The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK - see https://www.stack3d.com/2024/01/muscletech-nitro-tech-ripped-europe.html 

 

Muscletech® is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world. LeanBiome® will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and will be launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels.

 

LeanBiome® is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome® contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness (Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes (frontiersin.org)

 

 

Stephen OHara, CEO of OptiBiotix Health plc commented: "We are very pleased to announce the launch of LeanBiome® with such a well-known and internationally respected sports brand such as Muscletech®. LeanBiome® has been formulated to support anyone interested in improving their fitness for leisure or the elite athlete. It is supported by multiple published clinical studies which show it helps reduce body fat around the waist and hips, improving body leanness whilst enhancing the diversity of the gut microbiome to improve stamina and overall fitness.

 

"LeanBiome® is a unique product which is increasingly being recognised by major sports brands as a key differentiator from existing products and has the potential to have a major impact in the sports nutrition and health and fitness markets."

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

Duncan Vasey / Lucy Williams

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

About OptiBiotix www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBTMFTMTJBBBI
Date   Source Headline
20th Feb 20149:10 amRNSResult of Open Offer and Issue of Equity
3rd Feb 20144:31 pmRNSFurther re Open Offer
30th Jan 20144:37 pmRNSOffer Document Posted
30th Jan 20144:36 pmRNSAnnual Financial Report
28th Nov 20137:00 amRNSChange of Name
26th Nov 20137:00 amRNSChange of Rule 26 Website Address
25th Nov 201311:57 amRNSHolding(s) in Company
20th Nov 20131:21 pmRNSHolding(s) in Company
18th Nov 201312:53 pmPRNNotice of GM and Directorate Change
1st Nov 20134:05 pmPRNPosting of Circular
8th Aug 20137:00 amPRNUpdate
2nd Aug 20137:00 amPRNIssue of Equity - Conversion of Debt, Directors Dealing
25th Apr 20137:00 amPRNHalf-yearly Report
14th Mar 201311:19 amPRNResult of AGM, General Meeting and Issue of Equity
19th Feb 20137:00 amPRNNotice of General Meeting, AGM and Placing
31st Jan 20133:09 pmPRNFinal Results
6th Dec 201212:38 pmRNSNew Contract Win
15th Oct 20128:21 amRNSNew Product Approvals
12th Oct 20127:00 amPRNUpdate and Directorate Changeange
14th Sep 201211:30 amRNSProduct Approval
6th Sep 20127:00 amPRNNew Product Sales
3rd Sep 201210:54 amPRNChange of Adviser
3rd Sep 20128:55 amRNSNew Product Announcement
2nd Jul 20123:56 pmPRNTotal Voting Rights
18th Jun 201211:49 amPRNResult of General Meeting
14th Jun 201210:32 amPRNFurther re placing, update and grant of options
1st Jun 20123:22 pmPRNTotal Voting Rights
24th May 20127:00 amPRNPosting of Circular and change of registered office
22nd May 201211:30 amPRNPlacing and update
30th Apr 201212:00 pmPRNHalf-yearly Report
29th Feb 20121:20 pmPRNTotal Voting Rights
8th Feb 20127:01 amPRNIssue of Equity
8th Feb 20127:00 amPRNTrading Update
24th Jan 20127:00 amPRNHolding(s) in Company
19th Dec 201112:10 pmPRNResult of Annual General Meeting and Statement
2nd Dec 20117:00 amPRNDirectorate change and update
31st Oct 20112:16 pmPRNPosting of report and accounts
28th Oct 20117:00 amPRNFinal Results
23rd Sep 201110:38 amPRNShare Price Movement and Update
9th Sep 20117:00 amPRNFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.